Bradykinin

peptide

Kallikrein-generated vasodilatory mediator providing endothelial signaling and cardioprotection during acute thrombosis.

Pathway placement

Cascade stepCoagulation & thrombus formation

Confidencemedium

RationaleContact-phase activation byproduct; vasodilation and cardioprotection in acute injury.

Also acts inEndothelial activation/erosion

Druggability

Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresShared / rises in both

R — rupture / Type-I

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)-11

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationmag 2

2anemia / acute blood lossmag 3

3hypovolemia / dehydrationmag 2

4tachyarrhythmiamag 2

5hypoxemia / respiratory failuren/a

6hypertensive emergencymag 2

7high-demand / peri-operative stressmag 3

Coverage: 6/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 11 supporting references. See the discrimination table for all markers.

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)

Collection tube

K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)

Method / principle

Competitive/sandwich immunoassay or LC-MS/MS

Reagent / substrate

Anti-peptide antibody; or isotope-labeled internal standard (MS)

Platform

Immunoassay / LC-MS/MS

Turnaround · availability

Send-out / research · Research-grade